Despite PSA known as tPSA is the widely accepted biomarker for PCa, the overexpression level of which is also associated with other non‐cancerous prostate diseases, such as benign prostatic hyperplasia (BPH) and prostatitis.[2, 3] Consequently, it is hard for prostatologists to give an accurate diagnosis solely relying on elevated tPSA level, especially in the “diagnostic gray zone” of 4–10 ng mL−1. Here, KLK3 is linked to posterior cortical atrophy.